XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTANGIBLE ASSETS AND GOODWILL (Tables)
 9 Months Ended
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of components of intangible assets
The major components of intangible assets were as follows:
 
 
September 30, 2017
 
December 31, 2016
(in millions)
 
Gross
Carrying
Amount
 
Accumulated
Amortization,
Including
Impairments
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization,
Including
 Impairments
 
Net
Carrying
Amount
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
Product brands
 
$
20,768

 
$
(8,512
)
 
$
12,256

 
$
20,725

 
$
(6,883
)
 
$
13,842

Corporate brands
 
934

 
(161
)
 
773

 
999

 
(146
)
 
853

Product rights/patents
 
3,273

 
(2,290
)
 
983

 
4,240

 
(2,118
)
 
2,122

Partner relationships
 
172

 
(154
)
 
18

 
152

 
(128
)
 
24

Technology and other
 
212

 
(143
)
 
69

 
252

 
(160
)
 
92

Total finite-lived intangible assets
 
25,359

 
(11,260
)
 
14,099

 
26,368

 
(9,435
)
 
16,933

Acquired IPR&D not in service
 
226

 
—

 
226

 
253

 
—

 
253

B&L Trademark
 
1,698

 
—

 
1,698

 
1,698

 
—

 
1,698

 
 
$
27,283

 
$
(11,260
)
 
$
16,023

 
$
28,319

 
$
(9,435
)
 
$
18,884
Schedule of estimated aggregate amortization expense for each of the five succeeding years
Estimated amortization expense, for the remainder of 2017 and each of the five succeeding years ending December 31 and thereafter is as follows:
(in millions)
 
 
October through December 2017
 
$
584

2018
 
2,275

2019
 
2,059

2020
 
1,966

2021
 
1,781

2022
 
1,641

Thereafter
 
3,793

Total
 
$
14,099
Schedule of changes in the carrying amount of goodwill
The changes in the carrying amounts of goodwill during the nine months ended September 30, 2017 and the year ended December 31, 2016 were as follows:
(in millions)
 
Developed Markets
 
Emerging Markets
 
Bausch + Lomb/ International
 
Branded Rx
 
U.S. Diversified Products
 
Total
Balance, January 1, 2016
 
$
16,141

 
$
2,412

 
$
—

 
$
—

 
$
—

 
$
18,553

Acquisitions
 
1

 
—

 
—

 
—

 
—

 
1

Divestiture of a portfolio of neurology medical device products
 
(36
)
 
—

 
—

 
—

 
—

 
(36
)
Goodwill related to Ruconest® reclassified to assets held for sale
 
(37
)
 
—

 
—

 
—

 
—

 
(37
)
Foreign exchange and other
 
47

 
(12
)
 
—

 
—

 
—

 
35

Impairment to goodwill of the former U.S. reporting unit
 
(905
)
 
—

 
—

 
—

 
—

 
(905
)
Realignment of segment goodwill
 
(15,211
)
 
(2,400
)
 
6,708

 
7,873

 
3,030

 
—

Impairment to goodwill of the Salix reporting unit
 
—

 
—

 
—

 
(172
)
 
—

 
(172
)
Divestitures
 
—

 
—

 
(5
)
 
—

 
—

 
(5
)
Goodwill reclassified to assets held for sale
 
—

 
—

 
(947
)
 
(431
)
 
—

 
(1,378
)
Foreign exchange and other
 
—

 
—

 
(257
)
 
(5
)
 
—

 
(262
)
Balance, December 31, 2016
 
—

 
—

 
5,499

 
7,265

 
3,030

 
15,794

Realignment of segment goodwill
 
—

 
—

 
264

 
(264
)
 
—

 
—

Balance, January 1, 2017
 
—

 
—

 
5,763

 
7,001

 
3,030

 
15,794

Goodwill reclassified to assets held for sale
 
—

 
—

 
(31
)
 
(63
)
 
(76
)
 
(170
)
Impairment
 
—

 
—

 
—

 
(312
)
 
—

 
(312
)
Foreign exchange and other
 
—

 
—

 
262

 
(1
)
 
—

 
261

Balance, September 30, 2017
 
$
—

 
$
—

 
$
5,994

 
$
6,625

 
$
2,954

 
$
15,573